






Abbreviation		Mean GFP (SD)	% Annex+ within GFP+ (SD)
iCasp9 constructs			
F'F-C-Casp9		551 (55.8)	13.5 (3.3)
F'F-C-Casp9 _{C→S}		1268.5 (59.1)	2.6 (0.6)
F'F-Casp9		719 (60.2)	27.3 (4.5)
F-C-Casp9		788.5 (57.8)	26.5 (5.6)
F-Casp9		854 (61.1)	40.2 (9.4)

FIG. 1A




FIG. 1E

API903 induces dimerization of iCasp9 suicide gene, resulting in cell apoptosis




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6A




Fig. 6B




Fig. 7

Fig. 8A




Fig. 8B





Fig. 8C






Fig. 10A




Fig. 10B



Fig. 10C




Fig. 10D



Fig. 10E





Fig. 11A




Fig. 11B




Fig. 12 A




Fig. 12 B Assembly of FKBP-Caspase9 on a Frb Scaffold




Fig. 12 C




Fig. 13A

Fig. 13 B




Fig. 14C

Fig. 14B

Fig. 14A




Fig. 14D

Fig. 14E

Fig. 15A

Rimiducid




Fig. 15B

Rapamycin




Fig. 15C




Fig. 16A




Fig. 16B




Fig. 17A






Fig. 17B



C.



D. 24 Hours Post-Drug




Fig. 17D

E. 48 Hours Post-Drug




Fig. 17E




Fig. 18




Fig. 19




Fig. 20

Created with sequence

22/150




Fig. 21




Fig. 22




Fig. 23




Fig. 24




Fig. 25




Fig. 26




Fig. 27




Fig. 28




Fig. 29




Fig. 30




Fig. 31




Fig. 32




Fig. 33




Fig. 34





Fig. 35

37/150

Fig. 36






Fig. 38A




Fig. 38B




Fig. 39A




Fig. 39B




Fig. 40A





Fig. 40B



Created with SnapGene®




Fig. 41




Fig. 42

44/150

Fig. 43A Fig. 43B Fig. 43C




Fig. 44A

Fig. 44B




Fig. 45A




Fig. 45B




Fig. 45C




Fig. 46A

Fig. 46B

47/150

Fig. 46C




Fig. 47A

Fig. 47B




Fig. 47C

Fig. 47D

Fig. 48A

49/150

Fig. 48B




Fig. 49A




Fig. 49B

51/150

Fig. 49C




Fig. 49D

Fig. 50A

52/150





Fig. 50B

Figure 50C

53/150



54/150

Fig. 51A




Fig. 51B




Fig. 51C






Fig. 51D



(E) Fig. 51E






Fig. 53A

Fig. 53B




Fig. 54A




Fig. 54B






Fig. 55A




Donor	pBP	%CD3 ⁺ /CD3 ⁴	CD34 ⁺ MFI	% viability
920	NT	0.67	3.67	95.4
920	774	72.7	26.82	83.9
920	1433	76.01	28.74	73.3
920	1439	84.49	45.7	90.4
920	1440	73.86	23.5	77.8
920	1414	45.04	19.63	93.9
767	1414*	69.37	79.87	75.2
920	1151	71.75	43.08	74.2

Fig. 55B


60/150

Fig. 56A



Go-CAR vs MC-Rap-CAR

Fig. 56B



774 = MC-Fv-Fv-2A-CAR

1140 = MC-Fwt-FRB_L-2A-CAR

61/150

Fig. 57A

Fig. 57B





Fig. 58A

62/150



Tumor killing with DragCAR Constructs




Fig. 58B

T Cell Fraction





Fig. 58C



pBP1300--pSFG-FKBP.FRB.ΔC9.T2A-αCD19.Q.CD8stm.ζ.P2A-iMC
10,768 bp

Fig. 59




Fig. 60

65/150

Created with SnapGene®




Fig. 61






Fig. 62



pBP1316--pSFG-FKBP.FRBI.ΔC9.T2A-αPSCA.Q.CD8stm.ζ.P2A-iMC
10,741 bp

Fig. 63



pBP1317--pSFG-FKBP.FRB.ΔC9Q.T2A-αPSCA.Q.CD8stm.ζ.P2A-iMC
10,741 bp

Fig. 64




Fig. 65

Created with SnapGene®





Fig. 66

71/150

Created with SnapGene®



pBP1321--pSFG-FKBP.FRB.ΔC9.T2A-αPSCA.Q.CD8stm.ζ.P2A-MC.FKBPV.FKBP
10,741 bp

Fig. 67




Fig. 68A




Fig. 68B

Fig. 69 A




Fig. 69 B




Fig. 69 C




Fig. 69 D




Fig. 70 A




Fig. 70 B




Fig. 70 C

1494 (MC-FKBP-FRB_L-2A-iC9-2A-CAR) vs
1757 (FRB_L-FKBP-MC-2A-iC9-2A-CAR)




Fig. 70 D

1494 (MC-FKBP-FRB_L-2A-iC9-2A-CAR) vs
1757 (FRB_L-FKBP-MC-2A-iC9-2A-CAR)




Fig. 70E




Fig. 70 F HER2-DragCAR-3.0 vs SKOV3 at 1:10




Fig. 70 G HER2-DragCAR-3.0 vs SKBR3 at 1:1




Fig. 71 A








Fig. 71 B







81/150




Fig. 75 A




Fig. 75 B

Apoptosis determined by Incucyte after 12 hours drug treatment




Fig. 75 C




Fig. 75 D

Apoptosis determined by flow cytometry after 24 hours drug treatment






Fig. 76 A



87/150

Fig. 76 B



CONFIDENTIAL

ALU147-1

Fig. 76 C





Fig. 76 D






Fig. 77B




Fig. 77 C




Fig. 77 D




Fig. 78 A




Fig. 78 B






Fig. 78 C




93/150



94/150

Fig. 79 B




* $p < 0.05$
Two-way ANOVA (Bonferroni's multiple comparison test)

95/150

T cell count - [mCD45/CD3⁺] CD19⁺

Fig. 79 C



- There was significant difference in rapamycin-induced elimination of CD19⁺ cells.
- There was no significant reduction of CD19⁺ T cells with rimiducid treatment.

96/150

Fig. 79 D






Fig. 80




Fig. 81




Fig. 82




Fig. 83






Fig. 85




Fig. 86




Fig. 87





Fig. 88



pBP1296--pSFG-iMC.T2A-ahCD123(32716).ζ
 9253 bp

Fig. 89




Fig. 90




Fig. 91




Fig. 92




Fig. 93

111/150




Fig. 94



113/150





Fig. 96






Fig. 98

Created with SnapGene®




Fig. 99

117/150




Fig. 100




Fig. 101




Fig. 102




Fig. 103




Fig. 104








Fig. 105










Fig. 109A




Fig. 109C




Fig. 109C






Fig. 109D






Fig. 110C




FIG. 110D





Fig. 111












Fig. 112C

- 0 nM Rimiducid
- 0.1 nM Rimiducid
- ▲ 1 nM Rimiducid

Fig. 112D



U
m
4
4
50
- 000
LL






Fig. 113E

Fig. 113D

Fig. 114A





Fig. 114B






Fig. 114C






Fig. 114E

Fig. 114D






Fig. 116

SFG-PRAME TCR



Fig. 117A

SFG-ΔM-iMC.2A-ΔCD19 (iMC)



Fig. 117B

SFG-ΔM-iMC.2A-PRAME TCR (GoPRAME TCR)



Fig. 117C




Fig. 117D




Fig. 118A




Fig. 118B




Fig. 119A




Fig. 119B

- GoPRAME TCR
- GoPRAME TCR + rimiducid
- Go156 TCR
- Go156 TCR + rimiducid




Fig. 120A




Fig. 120B

- GoBob1 TCR
- GoBob1 TCR+ rimiducid
- Go156 TCR
- Go156 TCR + rimiducid




Fig. 121A




Fig. 121A




Fig. 121B




Fig. 121D

Fig. 121C